Media Coverage

Boehringer sales rocket in H1 following merger with Merial


Aug 03, 2017 - Animal Pharm

By Joseph Harvey
Animal Pharm
August 3, 2017 

In H1, Boehringer's animal health revenue reached €2.1 billion ($2.5 billion), up a remarkable 205% from the €688 million posted for the same period last year.

The firm's animal health sales represent over 20% of total net sales across the entire Boehringer business. In addition to being aided by the inclusion of Merial's net sales, Boehringer said its swine vaccine Ingelvac Circoflex provided the largest contribution to net sales.

Boehringer additionally benefited from strong performance of its companion animal antiparasitic lines Nexgard and Frontline, for protection against fleas and ticks.

Simone Menne, a member of the board of managing directors responsible for finance at the firm, commented: "Our net sales in animal health have more than tripled as a result of the integration of the Merial animal health business."

Hubertus von Baumbach, chairman of the board of managing directors, added: "After a phase of intensive change, we have now largely completed the extensive transformation of our company. Our goal is to set ourselves the greatest medical challenges with innovative medicines. In order to reach this goal, we are making above-average investments in the research and development of new therapeutic options. We are thereby making a contribution to improving the health of people and animals."

Ingleheim-headquartered Boehringer acquired Merial in January 2017. Following the merger, Ceva Santé Animale gained a range of products divested by the firm. Shortly before it was acquired by Boehringer, Merial reported strong growth of 7% for its fiscal 2017 in its final year with Sanofi.  

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum